Open AccessEncouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study
Author(s) -
Wen Zhang,
Yong Li,
Liyan Xue,
Dong Qu,
Zhichao Jiang,
Zhen Wang,
Zhaoyang Yang,
Aiping Zhou
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s298360
Subject(s) - medicine , capecitabine , chemotherapy , regimen , neutropenia , cisplatin , radiation therapy , oncology , leukopenia , surgery , neoadjuvant therapy , gastroenterology , cancer , breast cancer , colorectal cancer
To evaluate the efficacy and safety of neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma (ESCC).